Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598934 (tumor growth)
 58,965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lentinan, an antitumor polysaccharide from Lentinus edodes, was degraded to seven fractions by treatment with formic acid. The low molecular-weight fractions (I and II) showed no antitumor activity against sarcoma-180 solid-type tumor and the absorption maximum of Congo Red did not shift in their presence in 0.1M sodium hydroxide. The medium molecular-weight fraction III, which required the increase of doses (5 or 10 mg/kg) for inhibition of tumor growth, caused a little shift. On the other hand, the absorption maximum of Congo Red shifted largely by the presence of high molecular-weight fractions (IV approximately VII) which showed the inhibition ratio of over 95% in a dose of 1 mg/kg. Participation of molecular weight in the antitumor activity of polysaccharides which contain (1 leads to 3)-beta-D-glucan main chain was discussed.
 ...
PMID:Antitumor activity of degraded products of lentinan: its correlation with molecular weight. 96 51

Nutritional deficiencies are believed to be instrumental in producing reduced immune responses in a variety of animal species. Malnutrition may result in an increase or a decrease in immune functions, depending upon its degree, and also the timing and severity of the nutritional protein deprivation. Our experimental data suggest that there is a significant impairment of cytotoxic activity against K-562 and of the ability of spleen cells to produce interferon in protein-deprived mice in comparison with control mice. Paradoxically accelerated tumor growth after administration of OK-432 or Lentinan was also noted in protein-deficient tumor-bearing mice. In addition, a clinical randomized study of advanced or recurrent gastric cancer patients treated with MMC and FT(MF) with or without lentinan was performed. We recognized excellent end-point results only in the lentinan-treated patients with normal protein levels, while no effect of this agent was seen in patients with low serum protein levels (below 5.9/dl). Aggressive postoperative chemotherapy for cases with distant lymph node metastasis was performed under active nutritional support without any depression of metabolic and immunological states, resulting in a good 5-year survival rate (36.9%).
 ...
PMID:[Anti-cancer effects of BRMs associated with nutrition in cancer patients]. 338 33

During the course of aging, the weight percentage of organs such as kidney to body weight remain almost unchanged, whereas the weight of the thymus decreases significantly. The antitumor activity of Lentinan is constant in mice younger than 1 year (52 weeks). From 52 weeks, aging has a suppressive effect on antitumor activity. Even in aged mice, administration of Lentinan was shown to be effective, and better results were obtained through chronic administration, even with a smaller dose. Lentinan enhanced delayed cutaneous hypersensitivity in aged mice similarly to that in young mice. Thymus homogenate showed synergism with Lentinan in 2-year-old mice for suppression of tumor growth, although thymus homogenate alone showed no effect. These results show that Lentinan is effective as an anticancer immunopotentiator in aged animals in a similar way to young animals.
 ...
PMID:[Age-dependent anti-tumor activity of lentinan in mice]. 360 49

The cumulative effects of Lentinan and endocrine therapy on the growth of DMBA (7, 12-dimethyl benzanthracene)-induced mammary tumors of rats were studied. Multiple injection of Lentinan alone resulted in a slight degree of regression of the tumor growth, when administered to rats bearing mammary tumors of about 1 cm in size. Ovariectomy-adrenalectomy, ovariectomy, and adrenalectomy, which are performed as surgical endocrine therapy, resulted in a more marked regression of the tumor than that produced by Lentinan treatment alone. Furthermore, multiple injection of Lentinan performed on these mammary tumor-bearing rats which had received surgical endocrine therapy 2 weeks previously evoked a marked regression of tumor growth. However, no changes in growth curves and survival rates, compared with those of saline controls were observed, indicating that Lentinan might be a useful agent when combined with surgical endocrine therapy. Concurrent injection of Lentinan resulted in a slight augmentation, although the histamine sensitivity of tumor bearing rats which had previously received surgical endocrine therapy elevated greatly, compared with that of controls. By contrast administration of Tamoxifen, which is used for medical endocrine therapy, resulted in a lesser degree of regression than that observed following surgical endocrine therapy, and was also not greatly affected by Lentinan injection.
 ...
PMID:[Cumulative effects of lentinan and endocrine therapy on the growth of DMBA-induced mammary tumor in rats]. 643 Feb 43

Using C3H/He mice, the antitumor effect of lipopolysaccharide (LPS) alone and in combination with Lentinan extracted from Lentinus edodes was studied. The influence of LPS on cellular immunity and the antitumor effect of the tumor necrosis factor (TNF) were also examined. LPS, which was administered into mice with tumor, induced hemorrhagic necrosis of the tumor within 48 h, demonstrating a high antitumor effect. When LPS was used in combination with Lentinan, the tumor growth was significantly inhibited as compared to that in the control mice. The combination of LPS and Lentinan prevented a decrease in the delayed type hypersensitivity in tumor bearing mice. Application of rabbit serum containing TNF resulted in hemorrhagic necrosis of the tumor within 48 h, as with LPS.
 ...
PMID:Antitumor effect of bacterial lipopolysaccharide (LPS) alone and in combination with lentinan on MH-134 tumors in C3H/He mice. 670 86

Lentinan was evaluated initially against the Lewis (LL) and Madison 109 (M109) lung carcinomas implanted in the footpads of syngeneic mice. Activity in these tumor models was assessed by both reduction in early tumor growth rates and increases in life span and cures, relative to untreated control mice with tumors. Lentinan given i.p. to mice bearing LL footpad tumors caused a reduction in tumor growth rate in only one of three experiments and an increase in life span of 48% at one dose level on another occasion. In contrast, lentinan given i.p. to mice bearing M109 footpad tumors was consistently curative (50 to 70%) in three experiments despite the lack of an effect upon early tumor growth rate. In subsequent experiments, syngeneic mice were implanted s.c. with M109 or LL and treated with lentinan. Although lentinan had no substantial effect upon LL, 25 to 75% of mice bearing s.c. M109 tumors were cured in three separate experiments following early treatment initiation. Delayed lentinan therapy, initiated when s.c. M109 tumors were greater than 100 mg, also resulted in complete tumor regression and cure of 29 to 63% of the mice in three experiments. Surgical adjuvant immunotherapy of s.c. M109 using lentinan also improved survival rates over those obtained using surgery alone. Mice cured of s.c.-implanted M109 using lentinan, or surgery plus lentinan, but not surgery alone, survived a rechallenge with M109. The therapeutic effects of lentinan in mice implanted s.c. with B16 melanoma were inconsistent.
 ...
PMID:Immunotherapy of Madison 109 lung carcinoma and other murine tumors using lentinan. 670 58

1. Lentinan inhibited the proliferation of MH 134 ascites hepatoma transplanted subcutaneously into C3H/He mice, but its most favorite effect appeared when 1mg-2mg/Kg of lentinan was administered for 10 consecutive days from the eighth day after tumor transplantation, yielding a tumor proliferation-inhibition rate of 33% in the average tumor diameter. 2. In studying the average survival days by the chemotherapy of mitomycin C (MMC), 5-fluorouracil (5-FU), and cytosine arabinoside (Ara-C) in combination with lentinan, when both of these substances were administered concurrently in the second week of the tumor transplantation, average survival time was 29.2 days as compared to 20.5 days in the untreated group, 25.1 days in the group administered lentinan alone, and 22.0 days in the group receiving chemotherapy alone. 3. When the antitumor activity of lentinan was studied by the change in the macrophage migration inhibition activity (MI), it was found that in the untreated group MI activity disappeared on the 14th day after tumor transplantation, while in the group treated with lentinan observation of a positive activity in the spleen cells suggested a restorative action of lentinan of the immunity suppression accompanying the tumor growth.
 ...
PMID:[Antitumor effect of polysaccharide lentinan on C3H/He mice bearing MH134 ascites hepatoma]. 682 Sep 9

Immuno-chemotherapeutic effect on growth of 81B mammary tumor was studied in syngeneic C3H/He mice fed diet with low (D) or normal (N) protein content. 1. 5-FU 20 mg/kg. was given intra-peritoneal daily for 3 weeks. The tumor volume ratio (T/C) was significantly reduced on day 14 in both N and D-group mice. However, all mice were dead 2 weeks after administration of 5-FU in D-group mice. 2. Immuno-potentiator OK-432 (50 KE/kg,) or Lentinan (5 mg/kg,) was given i.p. daily for 3 weeks. The 81B tumor growth was inhibited on day 14 in N-group mice. However, the tumor growth was paradoxically accelerated after administration of these agents in D-group mice. Augmentation of the natural killer cell activity was recognized in N-group mice treated with OK-432 or Lentinan, but no change was seen in D-group mice. 3. After administration of 5-FU, intra-tumoral concentration of 5-FU was higher in N-group mice than that of in D-group mice.
 ...
PMID:[Effects of protein calorie intake on immuno- and chemotherapy]. 682 Sep 15

Lentinan inhibited the proliferation of MH-134 ascites hepatoma transplanted subcutaneously. The best result occurred when 1 mg-2 mg/kg of lentinan was administered for 10 consecutive days from the eighth day after tumor transplantation. Tumor proliferation was 33% inhibited as measured by the average tumor diameter. The average survival (days) when chemotherapy with mitomycin-C (MMC), 5-FU and Ara-C in combination with lentinan, was administered concurrently in the second week of the tumor transplantation was 29.2 days as compared to 20.5 days in the untreated group, 25.1 days in the group given lentinan alone, and 22.0 days in the group receiving chemotherapy alone. When lentinan was administered in combination with bacterial lipopolysaccharide (LPS), the group given lentinan for 5 consecutive days from the third day after tumor transplantation and 30 micrograms LPS i.p. on the thirteenth day, had 70% inhibition of tumor as measured by the average tumor weight. The antitumor activity of lentinan was studied by following changes in macrophage migration inhibition activity (MI). In the untreated group, MI activity disappeared on the 14th day after tumor transplantation. In the group treated with lentinan, spleen cells had positive activity suggesting a restorative action of lentinan on the immune suppression accompanying tumor growth.
 ...
PMID:Antitumor effect of polysaccharide lentinan on MH-134 ascites hepatoma in C3H/He mice. 706 33

To investigate the mechanism of tumor growth enhancement induced by operative stress in rats, laparo-thoracotomy was performed on day 2 after tumor cell inoculation associated with administrations of various kinds of immunopotentiators. OK-432 (Streptococcal preparation), PS-K (extract from mycelium of Coriolus Versicolor), Lentinan (extract from Lentinus Edodus) and C. parvum were administered intravenously or intraperitoneally in the fractionated form prior to or after inoculation. In general, administration of each immunopotentiator, except for Lentinan, resulted in a recovery from the reduction in survival days after laparo-thoracotomy. In particular, OK-432 administration prior to inoculation showed a significant improvement.
 ...
PMID:Survival time of tumor-bearing rats as related to operative stress and immunopotentiators. 710 60


1 2 Next >>